Patrys to initiate clinical trial with Onyx Pharmaceuticals
In November 2013, Patrys announced it would initiate an Investigator-sponsored clinical trial using PAT-SM6 in combination with Onyx Pharmaceuticals' carfilzomib.
PAT-SM6 clinical trial in multiple myeloma recruiting final cohort
In November 2012 Patrys commenced a Phase I/IIa clinical trial in multiple myeloma with anti-cancer drug PAT-SM6 at The University Hospital of Würzburg.
Peer reviewed publications support PAT-SM6 as an anti-cancer treatment
Patrys has recently focussed on submitting manuscripts to peer reviewed scientific publications in an effort to promote its products, technologies and platform which has not previously been done
PAT-SC1 shows significant survival benefit in gastric cancer trial
In September 2011, Patrys announced positive results from a follow-up of gastric cancer patients who were treated with anti-cancer compound PAT-SC1.
Frontpage Slideshow | Copyright © 2006-2011 JoomlaWorks Ltd.
